Tai-Seung Nam

Tai-Seung Nam

Auto-generated profile, based on publicly available information

Tai-Seung Nam

Department of Neurology, Chonnam National University Hospital and Medical School, Gwangju, Korea

Research Focus & Metrics

Academic Career Length

57Years (1970-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
YKYoung Nam Kwon
Young Nam Kwon
BKBoram Kim
Boram Kim
JKJun-Soon Kim
Jun-Soon Kim
HMHeejung Mo
Heejung Mo
KCKyomin Choi
Kyomin Choi
SKSung-Min Kim
Sung-Min Kim
Background and Objective To investigate the clinical relevance of CSF myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) testing in a large multicenter cohort. Methods In this multicenter cohort study, paired serum-CSF samples from 474 patients with suspected inflammatory demyelinating disease (IDD) from 11 referral hospitals were included. After serum screening, patients were grouped into seropositive myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD, 31), aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD, 60), other IDDs (217), multiple sclerosis (MS, 45), and non-IDDs (121). We then screened CSF for MOG-IgG and compared the clinical and serologic characteristics of patients uniquely positive for MOG-IgG in the CSF to seropositive patients with MOGAD. Results Nineteen patients with seropositive MOGAD (61.3%), 9 with other IDDs (CSF MOG + IDD, 4.1%), 4 with MS (8.9%), but none with AQP4-IgG + NMOSD nor with non-IDDs tested positive in the CSF for MOG-IgG. The clinical, pathologic, and prognostic features of patients uniquely positive for CSF MOG-IgG, with a non-MS phenotype, were comparable with those of seropositive MOGAD. Intrathecal MOG-IgG synthesis, observed from the onset of disease, was shown in 12 patients: 4 of 28 who were seropositive and 8 who were uniquely CSF positive, all of whom had involvement of either brain or spinal cord. Both CSF MOG-IgG titer and corrected CSF/serum MOG-IgG index, but not serum MOG-IgG titer, were associated with disability, CSF pleocytosis, and level of CSF proteins. Discussion CSF MOG-IgG is found in IDD other than MS and also in MS. In IDD other than MS, the CSF MOG-IgG positivity can support the diagnosis of MOGAD. The synthesis of MOG-IgG in the CNS of patients with MOGAD can be detected from the onset of the disease and is associated with the severity of the disease. Classification of Evidence This study provides Class II evidence that the presence of CSF MOG-IgG can improve the diagnosis of MOGAD in the absence of an MS phenotype, and intrathecal synthesis of MOG-IgG was associated with increased disability.

16 November 2011 in European Neurology
Verified
Journal Article
Closed access
JKJoon-Tae Kim
Joon-Tae Kim
MPMan-seok Park
Man-seok Park
GYGeum-Jin Yoon
Geum-Jin Yoon
HJHyunjung Jung
Hyunjung Jung
KCKang-Ho Choi
Kang-Ho Choi
KCKi-Hyun Cho
Ki-Hyun Cho
Background: Mood disorder is a frequent complication of stroke. Comorbid depressive and anxiety disorders are very common, indicating that it is advisable to assess both disorders at the same time. The aim of the present study was to examine the prevalence of post-stroke depression (PSD) and poststroke anxiety (PSA) at baseline and to evaluate factors related to delayed PSD and PSA at 3 months after stroke onset. Methods: This was a prospectively registered and retrospectively analyzed study of patients with acute ischemic stroke between January 2009 and March 2010. Patients included in this study were interviewed in order to evaluate their Hospital Anxiety and Depression Scale (HADS) scores. In this study, each depression and anxiety score was dichotomized into ‘nondepressive and nonanxious’ (HADS-D and HADS-A ≤7) and ‘depressive and anxious’ (HADS-D and HADS-A >7). Multiple logistic regression analysis was used to evaluate the independent factors of depressive and anxious symptoms 3 months after stroke onset. Results: Of the 133 patients, 47.4% were ‘depressive’ and 56.4% were ‘anxious’ at baseline. The depressive and anxious groups had a significantly higher frequency of severe white matter hyperintensity (WMH) than the nondepressive and nonanxious groups (p < 0.05). The independent factors of PSD and PSA at 3 months were deep white matter hyperintensities (DWMH) and modified Rankin scale 0 to 1 at 3 months. Conclusion: In conclusions, the results of our study demonstrated that delayed depression and anxiety after ischemic stroke were related to the severity of DWMH and unfavorable outcomes at 3 months, regardless of anti-anxiety treatment. Our results suggested that WMH might be associated with pathomechanism of delayed depression and anxiety.

1 January 2012 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
SCSeong-Min Choi
Seong-Min Choi
BCBang-Hoon Cho
Bang-Hoon Cho
KCKang-Ho Choi
Kang-Ho Choi
TNTai-Seung Nam
Tai-Seung Nam
JKJoon-Tae Kim
Joon-Tae Kim
KCKi-Hyun Cho
Ki-Hyun Cho
Choi SM, et al. J Clin Neurol. 2012 Mar;8(1):79-82. http://dx.doi.org/10.3988/jcn.2012.8.1.79

25 October 2017 in Journal of Healthcare Engineering
Verified
Journal Article
Open access
PDF file
SCSung-Joon Cho
Sung-Joon Cho
DBDonghak Byun
Donghak Byun
TNTai-Seung Nam
Tai-Seung Nam
SCSeok-Yong Choi
Seok-Yong Choi
BLByung-Geun Lee
Byung-Geun Lee
SKSohee Kim
Sohee Kim
Although additive manufacturing technologies, also known as 3D printing, were first introduced in the 1980s, they have recently gained remarkable popularity owing to decreased costs. 3D printing has already emerged as a viable technology in many industries; in particular, it is a good replacement for microfabrication technology. Microfabrication technology usually requires expensive clean room equipment and skilled engineers; however, 3D printing can reduce both cost and time dramatically. Although 3D printing technology has started to emerge into microfabrication manufacturing and medical applications, it is typically limited to creating mechanical structures such as hip prosthesis or dental implants. There have been increased interests in wearable devices and the critical part of such wearable devices is the sensing part to detect biosignals noninvasively. In this paper, we have built a 3D-printed sensor that can measure electroencephalogram and electrocardiogram from zebrafish. Despite measuring biosignals noninvasively from zebrafish has been known to be difficult due to that it is an underwater creature, we were able to successfully obtain electrophysiological information using the 3D-printed sensor. This 3D printing technique can accelerate the development of simple noninvasive sensors using affordable equipment and provide an economical solution to physiologists who are unfamiliar with complicated microfabrication techniques.

1 September 2011 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
TNTai-Seung Nam
Tai-Seung Nam
SLSeung-Han Lee
Seung-Han Lee
BKByeong-Chae Kim
Byeong-Chae Kim
KCKang-Ho Choi
Kang-Ho Choi
JKJoon-Tae Kim
Joon-Tae Kim
MLMin-Cheol Lee
Min-Cheol Lee

1 January 2025 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
SKSu-Hyun Kim
Su-Hyun Kim
JMJoo Min
Joo Min
SKSung-Min Kim
Sung-Min Kim
ELEun-Jae Lee
Eun-Jae Lee
YLYoung-Min Lim
Young-Min Lim
HKHo Jin Kim
Ho Jin Kim
Kim SH, et al. J Clin Neurol. 2025 Mar;21(2):131-136. https://doi.org/10.3988/jcn.2024.0485